Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Metabolism and Disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species.

Post N, Yu R, Greenlee S, Gaus H, Hurh E, Matson J, Wang Y.

Drug Metab Dispos. 2019 Oct;47(10):1164-1173. doi: 10.1124/dmd.119.087395. Epub 2019 Jul 26.

PMID:
31350288
2.

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.

Alexander VJ, Xia S, Hurh E, Hughes SG, O'Dea L, Geary RS, Witztum JL, Tsimikas S.

Eur Heart J. 2019 Sep 1;40(33):2785-2796. doi: 10.1093/eurheartj/ehz209.

3.

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs.

Shemesh CS, Yu RZ, Warren MS, Liu M, Jahic M, Nichols B, Post N, Lin S, Norris DA, Hurh E, Huang J, Watanabe T, Henry SP, Wang Y.

Mol Ther Nucleic Acids. 2017 Dec 15;9:34-47. doi: 10.1016/j.omtn.2017.08.012. Epub 2017 Aug 30.

4.

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

Kieran MW, Chisholm J, Casanova M, Brandes AA, Aerts I, Bouffet E, Bailey S, Leary S, MacDonald TJ, Mechinaud F, Cohen KJ, Riccardi R, Mason W, Hargrave D, Kalambakas S, Deshpande P, Tai F, Hurh E, Geoerger B.

Neuro Oncol. 2017 Oct 19;19(11):1542-1552. doi: 10.1093/neuonc/nox109.

5.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

7.
8.

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.

Goel V, Hurh E, Stein A, Nedelman J, Zhou J, Chiparus O, Huang PH, Gogov S, Sellami D.

Cancer Chemother Pharmacol. 2016 Apr;77(4):745-55. doi: 10.1007/s00280-016-2982-1. Epub 2016 Feb 22.

PMID:
26898300
9.

Nilotinib versus imatinib for GIST - Authors' reply.

Blay JY, Hurh E, Green S, Novick S.

Lancet Oncol. 2015 Jul;16(7):e311-2. doi: 10.1016/S1470-2045(15)00016-9. No abstract available.

PMID:
26149878
10.

Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.

Zollinger M, Lozac'h F, Hurh E, Emotte C, Bauly H, Swart P.

Cancer Chemother Pharmacol. 2014 Jul;74(1):63-75. doi: 10.1007/s00280-014-2468-y. Epub 2014 May 10.

PMID:
24817600
11.

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC.

Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12.

12.

AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.

Oliner JD, Bready J, Nguyen L, Estrada J, Hurh E, Ma H, Pretorius J, Fanslow W, Nork TM, Leedle RA, Kaufman S, Coxon A.

Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2170-80. doi: 10.1167/iovs.11-7381.

PMID:
22410553
13.

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA.

Clin Pharmacokinet. 2011 Feb;50(2):131-42. doi: 10.2165/11537430-000000000-00000.

PMID:
21241072
14.

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcón BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD.

Mol Cancer Ther. 2010 Oct;9(10):2641-51. doi: 10.1158/1535-7163.MCT-10-0213.

15.

2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.

Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.

Int J Oncol. 2010 Oct;37(4):1023-30.

PMID:
20811725
16.

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT.

Blood. 2009 Mar 19;113(12):2637-45. doi: 10.1182/blood-2008-07-168583. Epub 2008 Nov 3.

17.

Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines.

Guan N, Korukonda R, Hurh E, Schmittgen TD, Donkor IO, Dalton JT.

Int J Oncol. 2006 Sep;29(3):655-63.

PMID:
16865282
18.

Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150.

Wu D, George TG, Hurh E, Werbovetz KA, Dalton JT.

Life Sci. 2006 Aug 8;79(11):1081-93. Epub 2006 Mar 28.

PMID:
16643960
19.

SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: a novel class of cytotoxic agents for prostate cancer.

Gududuru V, Hurh E, Sullivan J, Dalton JT, Miller DD.

Bioorg Med Chem Lett. 2005 Sep 15;15(18):4010-3.

PMID:
16005217
20.

Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer.

Gududuru V, Hurh E, Dalton JT, Miller DD.

J Med Chem. 2005 Apr 7;48(7):2584-8.

PMID:
15801848
21.

Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer.

Gududuru V, Hurh E, Dalton JT, Miller DD.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5289-93.

PMID:
15454213
22.

Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer.

Gududuru V, Hurh E, Durgam GG, Hong SS, Sardar VM, Xu H, Dalton JT, Miller DD.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4919-23.

PMID:
15341952
23.

Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats.

Hurh E, Lee EJ, Kim YG, Kim SY, Kim SH, Kim YC, Lee MG.

Res Commun Mol Pathol Pharmacol. 2000;108(3-4):261-73.

PMID:
11913717
24.

Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats.

Hurh E, Lee EJ, Kim YG, Kim SY, Kim SH, Kim YC, Lee MG.

Biopharm Drug Dispos. 2000 Nov;21(8):331-8.

PMID:
11514953
25.

Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats.

Hurh E, Lee E, Lee A, Kim Y, Kim S, Kim S, Lee M.

Biopharm Drug Dispos. 2000 Jul;21(5):193-204.

PMID:
11180198

Supplemental Content

Support Center